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Theoretical and practical issues involved in integrating pharmocotherapy and psychosocial
therapy in a long-term day hospital for schizophrenics are addressed. The limitations and risks of
relying too heavily on a biomedical conceptual framework are discussed. In addition to diagnosis,
target symptoms, pharmacodynamics, and pharmacokinetics, individual interpersonal, family,
and institutional dynamics can exert profound effects on theeffectiveness ofmedication. Through
case illustrations it is shown how an open systems model and a group approach can allow for an
integration ofthe many variables involved in the medication process. A weekly medication group
which emphasizes education, informed choice, patient responsibility, and the examination of the
boundary between medication effect and the need for psychological work is described. It is shown
that the chemical control of psychosis alone may reinforce the psychosocial aspects of the
schizophrenic syndrome. A distinction is drawn between chemical control of psychosis and the
sensitive use ofmedication as a facilitator ofgrowth-promoting psychosocial treatment.
According to a recent book, well reviewed by a number of prominent psychiatrists,
Hamlet's problem was a bipolar affective disorder. The author thus reduces the
existential, social, familial, and psychological dimensions so richly interwoven by
Shakespeare to a chemical imbalance. It has often been the lot ofthe psychotherapist
grappling with the schizophrenic and his family to encounter such reductions as
"Everything was fine until he fell off his tricycle when he was three," or "We had a
wonderful family until she started smoking pot when she was seventeen." This kind of
explanation has often been invoked to alleviate guilt and to fend off the painful
explorations necessary for in-depth understanding. Books and articles like The Broken
Brain that are popularizing the swing toward biological psychiatry are lending
credence to the families' defensive metaphors as literal reality supported by the
authority ofscience.
Carol, a 26-year-old woman was brought to see me after she had refused to
take medication and had signed herself out of a psychiatric hospital. She
manifested obvious psychotic symptoms and outlined a life history consistent
with a DSM III diagnosis of schizophrenia. But, like every schizophrenic, she
also had a healthy side striving to individuate and develop. She expressed
concerns about being trapped in a hospital or forced to take medicine by court
order which she feared might convert her into a twitching robot such as she saw
in the hospital. She denounced the hospital for trying to control her and
discredit her plans for independence, her thoughts and feelings, just as her
family had done. She felt that both hospital and familyjustified their control by
saying that something was wrong with her brain. In Carol's mother's mind a
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placenta previa birth and a seizure at age three had led to her daughter's
disordered brain, requiring her to be protected and controlled. Independence
was out of the question. Mother insisted that Carol had a memory defect; her
evidence was that Carol responded to such questions as "What happened in
school today?" by answering, "Nothing." When I recommended more family
meetings and raised questions about Carol's alleged "defective mind" based on
my experience with Carol, her mother triumphantly handed me a copy of The
Broken Brain with the following passage underlined:
"While episodes ofillness are sometimes triggered by unfortunate life events,
the basic causes lie in the biology of the brain. The best way to treat these
biological abnormalities-treatment that is not always available at present-is
to correct the underlying physical abnormality, usually through the use of
somatic therapy" [1].
This book heralds the remarkable advances in biological psychiatry as the beginning
of a psychiatric revolution that will lead to a brave new world for sufferers of mental
illness in which no one will experience blame, stigma, or guilt. Mental patients will be
treated with compassion and chemicals. Carol, in her flight from the hospital, was
reacting to a meta-level message contained within the superficially more benevolent
one. She experienced the insistence on fixing her broken brain as an invalidation of her
perceptions and her healthy ego strivings.
Like the doctor from whom Carol was running, it occurred to me as a psychiatrist of
the 1980s that Carol needed a neuroleptic despite what she had to say against it: she
was suffering from a thought disorder. The collaborative NIH study [2], the May
study [3], and many more like them demonstrate the efficacy of neuroleptics and their
superiority over all other interventions. The Rosenthal and Kety studies [4] demon-
strating genetic factors in schizophrenia, the new technologies on the brink of
establishing biological markers, neurotransmitter research, and the plethora ofarticles
and accounts in the media about schizophrenia being a chemical imbalance that my
patients' families bring to me on a regular basis-these seemed compelling reasons
why I should reach for a pill or a syringe to get a neuroleptic into Carol. If I did not find
a way to get Carol to comply, might there be grounds for a malpractice suit?
On the other hand, I admired Carol's spark of healthy ego trying to fight off
psychotic collapse, as she tried to hold her own in a conflict of interest with her family
and to strike out on her own. It also seemed to me that in some ways Carol was being
more scientific than the biological psychiatrists by insisting that her problems could
not be understood without understanding her family's role.
While the modern technology of biological psychiatry is impressive, the more
profound scientific revolution, however, is an epistemological shift from an Aristotelian
linear cause-and-effect model of thinking to a systems framework which is predicated
on multiple causation and complex interrelationships. In his last work, Levels of
Schizophrenia, Scheflen [5] examines this revolution as it pertains to schizophrenia.
Unlike Szas, who believes that schizophrenia is a bogus category manufactured by
society and the mental health establishment, Scheflen maintains that schizophrenia is
quite real, but too complex to fit into a DSM-type categorization, with its exclusive
focus on the illness ofan individual. He delineates a system of eight interacting levels to
describe the schizophrenic syndrome: the neural fields, the neurotransmission system,
the nervous system, the schizophrenic person, the dyadic relationship, the family,
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mental health institutions, and society. Failure at one level of organization can be
rectified by processes or interventions at the next higher level of organization or
deviance can be increased by non-compensating responses. If there is not sufficient
rectification at each successive level, deviance reaches a critical point at which, in
cybernetic terms, there is a runaway situation manifesting as a psychotic disorganiza-
tion in the vulnerable schizophrenic person.
Observing a living social system is analogous to examining a smaller, biological
system through a microscope. The different size and appearance of the fields that we
see at different magnifications depend on focus and perspective, but each level
interacts with and affects every other level. The same is true in a schizophrenic system.
A dysfunction of neural fields or the neurotransmitter in the limbic system, perhaps
genetically determined, could be either compensated for or exacerbated by the
mother's response at the dyadic level. Problems of mother-infant responsiveness could
be compensated for or exacerbated by the family's response to the problems in the
dyad. The family in turn is affected by the response of the mental health system, and
the mental health system by society and its institutions. Findings from anthropology of
dramatic differences in the outcome in schizophrenia between third-world and western
cultures, findings from neurophysiology which suggest that quality of interaction and
the early experience of the infant have bearing on proliferation of neural networks
(Scheflen [5]), findings from sociopharmacology that doctor-patient relationships and
ward culture have a bearing on the effect and potency of psychoactive chemicals
(Barchas and Barchas [61)-all point to the imperative of a systems concept to make
coherence out ofschizophrenia and the treatment process.
Scheflen also makes an important distinction between the psychotic and non-
psychotic facets of the schizophrenic condition. It is the non-psychotic, so-called
negative symptoms that resist our direct interventions, while psychosis usually
succumbs to our arsenals of antipsychotics and directive management. Strauss and
Carpenter [7], in their psychosocial biological development model of schizophrenia,
stress the maturational arrest in the schizophrenic that leaves the individual socially
inept, dependent on a symbiosis-like attachment, and vulnerable to the emotional
fallout that is a by-product of relationships with others. The schizophrenic is on the
horns ofthe need/fear dilemna and seeks sanctuary in psychosis or withdrawn states of
non-experience (Ogden [8]). In my experience, most psychotic episodes in schizophre-
nics are triggered by the loss or threatened loss ofsymbiotic attachments. This includes
not only the physical or emotional abandonment by the symbiotic partner but also can
involve a growth step taken by the patient that is experienced as a harbinger ofthe loss
of symbiotic ties. Treatment with neuroleptics and re-establishing the patient's
symbiotic attachment with family or institutional surrogate (such as hospital or
halfway house) control most psychotic episodes with alacrity and efficiency and are the
standard fare today. This treatment alone, however, leaves thepatient enmeshed in the
family or the mental health system without impetus for individuation and relegates
him or her to the chronic mental patient role, possibly for life. If, however, treatment
addresses the developmental dimension of the patient's problem by providing a
treatment system that promotes social interaction and learning throughexperience and
identifies and contends with thecomplex and often covertanti-therapeutic forcesofthe
system, then the picture can be more hopeful. Rather than receiving treatment which
consists solely ofcontrol ofpsychosis, schizophrenics need to be involved in a treatment
which helps them to develop as individuals. For the past fifteen years, I have been
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director of a small program that attempts such personal development of our schizo-
phrenic patients.
Our day program in Washington, D.C., is housed in an old school building. This
seems fitting, since our philosophy stresses learning more than the treatment of
disease. Our census averages 20 to 25 patients; duration of treatment ranges from
several months to several years. The vast majority of our patients have had more than
one psychotic episode and several previous inpatient hospitalizations; most carry the
diagnosis of schizophrenia. For the most part, they live in the community in halfway
houses, in group homes, and a few in apartments. They are trying to make an
adjustment to life in the community rather than in a state hospital.
As a result of budget cuts three years ago, we lost a psychiatrist's position, requiring
me to take on the role of pharmacotherapist in addition to my role as clinical director,
sociotherapist, and group and family therapist. It has been a great surprise to me to
find that it is in the role of pharmacotherapist that I have had to grapple most directly
with pressures from patients, families, and other treatment systems that threaten to
subvert the fundamentals of our treatment philosophy. The notion that schizophrenia
isjust a chemical imbalance that can be fixed by a chemical is legitimized in the minds
ofpatients and family by the swing to biological psychiatry in the media. It is this myth
that is often invoked when fears and tensions in the therapeutic process run high; it can
present a formidable resistance to therapeutic work.
In a multiple family group, Jim complained that his father had been swearing
and screaming at him for weeks and that he was afraid that this might drive him
to retaliate. His mother had earlier revealed that Jim's father, who does not
attend the meetings, was having a hard time adjusting to imminent retirement.
At this point, however, she disregarded her son's protest and complained to the
therapist that Jim was not taking his medication regularly. "I read an article in
the newspaper by Dr. Fuller Torrey," she continued, "that schizophrenia is
caused by a chemical imbalance in the brain, and Jim is certainly out of
balance." Efforts by the co-therapists to encourage her to consider what Jim
was saying were drowned out by her escalating complaints to the psychiatrist
for not being forceful enough with Jim's medication. Two other mothers joined
the attack on the psychiatrist in support of Jim's mother, asserting that their
sons are fine when they take their medication but don't make any sense when
they don't. Bill, a recovering schizophrenic who hasn't had a psychotic episode
in four years, then tried to get Jim's mother to listen to her son. He recounted
his struggle with his parents to take his feelings seriously instead ofjamming a
pill down his throat when he got angry. At first Jim's mother attacked and tried
to discredit Bill, but when Bill's mother echoed Bill's position, Jim's mother
began to consider that perhaps she should listen to her son. The beginnings of a
dialogue between Jim and his mother ensued in which they discussed their
common problem with Jim's depressed, angry father.
The work on expressed emotionality and the development of non-exploratory
educational approaches in family therapy represent a promising direction that
appreciates the vulnerability of the schizophrenic member and the importance of a
positive treatment alliance with the family (Brown et al. [9]). Recent evidence suggests
that approaches embodying these insights can be effective in minimizing the noxious
effects ofblaming, excessive guilt, and acrimony, and reduce the incidence of psychotic
flareups. If the unconscious tendency to lock the schizophrenic into a role in which
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observations, thoughts, and feelings are invalidated is not addressed, however, the
non-psychotic part oftheschizophrenic condition can be deepened. As in Jim's case, if
the reductionism that schizophrenia is just a chemical imbalance is supported by the
therapist, the result is also support for pathological symbiosis, denial of the obvious rift
between mother and father, and invalidation of the patient's accurate perceptions.
Many patients believe that they are incapable of thinking and feeling in any
constructive way. Ogden suggests that the withdrawn non-responsive states where
many schizophrenics spend a great deal of their time are manifestations of the
schizophrenic's identification with the part of the mother who could not receive and
metabolize their projections as infants. He theorizes that, as a result ofthis internaliza-
tion, the potential schizophrenic literally shuts off the apparatus in the brain necessary
to receive and process experience, thus accounting for the maturational arrests.
Medication used inappropriately when feelings are beginning to awaken in the patient
can reinforce the patient's conviction that he cannot learn by experience.
Jane is a 36-year-old recovering schizophrenic who spent her adolescence
through age 28 as a revolving-door schizophrenic with frequent psychotic
exacerbations. While a patient at our day hospital, an outside psychiatrist gave
her megadoses of tranquilizers and neuroleptics, as well as several courses of
ECT, that blotted out feelings and thoughts each time she seemed on the
threshold ofmaking developmental steps. Jane has now been working with me
in individual psychotherapy for the past several years. She is living on her own,
working, and has been free ofpsychotic relapses for six years. She has recently
noticed that the frequent nightmarish feeling, at times a delusion, that her brain
isbeing sliced topieces, follows times ofanger or awareness ofthoughts that she
feels are likely to be controversial. We have come to understand that this state is
an internalization of her experience that her mother could not stand for her to
think or feel. Thus, symbolically she destroys her brain in order to protect her
symbiotic attachment to her mother. When her doctor used excessive medica-
tion or ECT, often at her request, he lived out the transference and deepened
her despair.
The challenging task for me as the day hospital pharmacotherapist has been to
prescribe medication in a way that helps the patient reduce emotional turbulence and
psychotic remissions without joining the unconscious forces within the patient, the
family, the treatment system, and within myself, that abort the process of learning
through experience and the development of capacities to think and feel.
To work with these problems, our program established a medication group. It meets
weekly for an hour and fifteen minutes and is open to all patients taking medication as
well as to other patients and staffwho are interested. Despite the fact that the emphasis
in our program is psychosocial, we felt that such a group was needed to recognize that
medication plays a central role in the lives of many of the patients and has enabled
many of them to decrease the frequency and severity of psychotic episodes. Rather
than thinking of our task as increasing or ensuring compliance, we have tried to
engender a culture in which patients are responsible for making choices about
medication based on information, recommendations from the pharmacotherapist, and
consultation with the group. An approach which emphasizes compliance implies a
passive-dependent role for the patient that resonates with symbiotic family relation-
ships. These strategies often validate patients' feelings of powerlessness and paranoid
thinking. Our framework attempts to enlist the patient's healthy ego to process
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information and make active decisions based on self-interest, allowing not only for the
chemical benefits of medication but for an increase of the experience of mastery and
self-differentiation. It was striking how little patients knew about medication when we
startedthegroup-given what a central roleit has played in their lives. Therewas little
overtcuriosity, but under thesurface there was theatmosphereofwhat a sex education
course might have been like in Victorian times. One patient referred to the group as
"the place where you can find out what you always wanted to know about medication
and were afraid to ask." At times I have felt too successful in creating a climate of
curiosity when patients confront me with more sophisticated questions than I am
prepared to answer! I have been forced to study the literature on pharmacology or face
embarrassment. I have been extremely impressed with how patients who seemed
totally indifferent, hostile, or on the far fringes of their delusional world can become
experts on pharmacology.
"Who has medication issues?" This is the way I begin each meeting. It is an
invitation to the patient's ego to join me in a collaboration in which each we have an
active and responsible role. In answer to questions from patients about particular
medications, I discuss with them what is known and what is uncertain, avoiding cliches
and half-truths. We cover topics such as the benefit/risk equation with each medica-
tion, including side effects; tardive dyskinesia; rationale for different drug strategies,
including minimum effective dose, intermittent, and symptomatic use; and the
rationale for use ofother drugs such as anticholinergics, antidepressants, and lithium.
We often consider the role of life style, diet, exercise, and deleterious effects of
non-prescriptiondrugssuch asstimulants and streetdrugs. Thepatient is helpedbythe
group to sortthrough which ofhis or her difficulties are amenable tomedication, which
require psychological work. We look at the possible investment in being psychotic as a
life choice. Rather than exploiting transference or using indoctrination techniques, the
patient is encouraged to make an informed choice about medication based on the best
scientific information with recommendations from the group and the doctor. It is
understood that thedoctorwill notprescribeanymedication that islikelytobeharmful
to the patient.
Attimes, theexigencies ofa group processwith disturbed patients requires an active
focusing on my part, or process-oriented interventions, to restore a work group in the
face of basic assumption pressure. For the most part, though, the group format has
provided much richer examination and working through than individual medication
transactions. The prescribing of a substance to be taken into the body through the
mouth during moments of distress is likely to evoke in the patient intense feelings
reminiscent of the infant-mother breastfeeding experience. Ifthe introjects ofthe bad
poisonous destructive breast have notbeen adequatelymetabolized, as they rarely have
been in the schizophrenic patient, then the patient may well experience at a conscious
or unconscious level themedication process as an attempt topoison, destroy, or envelop
him. The doctor, in turn feeling himself to be perceived as destructive, may be pushed
todefensive postures to protect himselffromdamage to his own self-esteem. Thegroup
provides a buffer against this situation, diffusing its intensity and introducing
ego-oriented concerns. The mother-child dyad is less compellingly recreated. The
group assists the patient and the doctor to negotiate in the emotion-laden process of
giving and taking in.
In a recent medication group, John requested that I prescribe an anti-
hypertensive drug for him. He had been taking Prolixin but also uses whatever
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street drugs he can get when he feels emotional pain. John seems to have
concluded that drugs are the only answer to problems or pain. This belief has
been reinformed by similar attitudes in his family, in which his father is an
alcoholic and his mother uses Valium heavily. A previous psychiatrist had put
John on megadoses of neuroleptics, focusing treatment on his lack of
compliance with medication. I responded naively to John's request for an
anti-hypertensive drug that I didn't know he had a blood-pressure problem.
John explained that he meant an anti-tension drug. He described feeling a
burning inside when he tries to have "an eye to eye" with a person who is
"against" him. Another patient asked him who his conflict was with, to which
John responded irritably that he was fed up with talking therapy and wanted a
"soothing from a drug." I responded that the Prolixin he was taking withpro re
nata provision was probably the best anti-tension medication for him at this
time. We could consider other medications in that class, but this might be a
matter of the limits of medication. Perhaps he needed to work on how to be in
conflict with another person and accept and manage the angry feeling. John
boomed back that I make him swallow the damned Prolixin that keeps him
dopey and under my thumb; that I have a panacea butjust won't let him have it.
I suggested we could explore the possibility that a lower dose ofProlixin might
help. He exploded, "You people have me in a bind! I get all cut upby my family
if I don't swallow what they want. My mother can get any goddamned
happiness pill shewants but you won't dothe same for me." At thispoint I felt a
counter-surge ofanger that this fellow was beinginfuriating. While I wastrying
to sort through the projections and countertransference, several patients
intervened to remind John that I had not forced him to take anything and that
he has to learn to experience some uncomfortable feelings. Another patient
shouted at John that he wanted to have his cake and eat it, too-"Stop being
such a baby!" John flushed and stood up as if to leave the room, but Janice,
another patient, asked him to stay. For many years she had had numerous
psychotic episodes requiring hospitalizations that had been fueled by street
drugs. She and I had enacted many similar confrontations in the past, but for
the last three years she had been free of psychosis and had been struggling to
face reality without numbing drugs. She and John were friends, and I felt that
at this moment her credentials with John were better than mine, despite her
paranoid style and persistent delusion that she was the messenger of God. She
told the group that we must be patient with John because he was trying to help
himself. Sheshared feelings about how hard it is to face lifewithout escapesand
delusions or drugs when reality seems so barren and pointless. Tempers cooled,
and John and I then were able to work out an accommodation which involved
continuing the Prolixin and trying to use therapy groups and trusted people to
help him manage painful or overwhelming feelings. While John has continued
to knock out his thinking and feeling capacities -under stress, either through
drugs or withdrawal, slowly he is bringing more ofhimselfinto the community,
and thegroup's ability tocontain hisprojections and rage arehelping todevelop
trust.
Themedication group has been an invaluable place toworkon thecomplex interplay
of the physiological, intrapsychic, interpersonal, and social aspects of the medication
process. Medical dynamics, however, extend into all phases of the program and
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particularly exert influence on the boundary between our program and families,
outside mental health institutions, and other people and institutions involved in the
patient's network. As Scheflen points out, in addition to the therapeutic and altruistic
motives that are elicited by the schizophrenic's painful predicament, there is an
unconscious investment in keeping him schizophrenic. The symbiotic partner needs a
partner; the family needs a repository, or glue; the hospitals and halfway houses need
customers; and society needs the insane as a frame of reference and as a basis for
exerting social control outside of the legal domain. The patient colludes with those
forces to the extent to which he is invested in a career as a chronic mental patient.
Medication can also be used as a chemical and symbolic restraint to help keep the
patient locked in the disenfranchised schizophrenic role, thus maintaining the equilib-
rium ofthe system.
The interplay of these forces emerged dramatically in our work with Tom, a
thirty-year-old man. He had been floundering at home with his parents, failing at one
job after another, and drifting aimlessly in schizophrenic fashion. His father was his
symbiotic partner, frantically trying to bail him out of difficulties, prop him up, and
direct his life. When the father died suddenly, Tom's passive-dependent and fragile
mother could offer little support to her son. Tom began wandering the city and was
literally picked up off the streets by Ms. M., a young woman who had left her young
children with her estranged husband to start a shelter for the homeless. Tom became
her most steadfast client, and Tom's familysupported this. It was as iftheyhad hired a
surrogate symbiotic partner for Tom, to protect his infirm mother. Tom was very
attracted to Ms. M. but also rebelled against her authoritarian ways, as he had done
with his father. He tried to re-establish his relationship with his father's associates,
particularly at an exclusive club where he had accompanied his father on many
occasions. He was thrown out by securityguards whofound his behavior inappropriate
and hostile. He told Ms. M. that he felt likedoing a "Hinckley number" on theguards.
Ms. M. called the Secret Service and within hours Tom was remanded to St.
Elizabeth's State Hospital's forensic unit, where he was started on high doses of
intramuscular Prolixin, pending trial forthreatening thelifeofthePresident. Sincethe
evidence against Tom seemed insubstantial, after a few weeks Tom's lawyer, the
family, and Ms. M. were able to reach an agreement with the District Attorney to
release Tom to the custody of Ms. M. and the family on the stipulation that he would
also receive psychiatric treatment. Tom entered our day hospital program.
At the day hospital Tom spent a good portion of the time sprawled on the couch in
the day room or staring blankly through groups. When addressed by other patients or
staff about what he was feeling or why he was in the program, his response was
mechanical: he was fine but he was forced by his lawyer to come. Tom's first initiative
came in the medication group when he requested that his medication be reduced or
stopped, or that he might at least take pills instead of injections. He asserted that his
only problem was the medication. He said that he was groggy and too tired to think or
move and that hecouldn't runor play ball as he used to. As weexplored Tom's request,
it seemed reasonable to the group and myself that some reduction in medication was
indicated, at least to determine if his flatness and withdrawal might be in part a side
effect of the Prolixin. However, Tom then expressed reluctance to change anything,
because of fear of being forced to go back to St. Elizabeth's. It was the recommenda-
tion of the group that Tom negotiate this problem with his lawyer, his family, and
Ms. M. in the Orientation Group, a weekly open group to which patients invite
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significant others. The group's goal is to involve these others in our treatment program
and at times to negotiate boundary issues like this one.
What followed felt like an assault which could be understood as the system resisting
a threatening change. Prior to the meeting at which these "significant others" were to
be present, I received a call from a Secret Service agent inquiring about Tom's
treatment. While the agent was proper and respectful, this had a somewhat intimidat-
ing effect on me. Ms. M. also called, demanding that she be informed ofany change in
Tom's medication. She said that if she were not treated more like a colleague, she
would pull Tom out of the program. Tom's mother and brother, who had been
attending the group for significant others regularly and had been supportive of the
program, were cold and hostile when they brought the lawyer to the meeting. Tom's
brother was incensed that Tom would consider stopping his medication "after all the
family had been through." He invoked the chemical imbalance argument and
threatened to personally drag Tom by the scruff of the neck back to the hospital if he
changed his medication. Tom's lawyer added that if he stopped without the District
Attorney's approval he might have to go back to the hospital, later standing trial which
could result in his going to jail. The lawyer later confided to me that the chances of
Tom's being convicted were non-existent since Ms. M's testimony was the only
evidence, and there were many problems with hercredibility. He added that hehad not
stressed this with Tom because he agreed with the family that Tom needed treatment,
and perhaps legal leverage was necessary. (Furthermore, the District Attorney was
particularly nervous in the climate of the Hinckley affair.) After several weeks of
difficult work with Tom and his network, the medication was reduced. The results were
undramatic except that Tom was more responsive in meetings and could resume his
athletic activities.
It was striking that the initial response to the prospect of a change in medication in
Tom's network was a dramatic, forceful resistance. On the surface was an overt
expressed fear of the potential destructive ravages of acute psychosis on an individual,
a family, and possibly society. This is a serious issue that must be weighed in any
decision to stop or reduce a neuroleptic in a patient with a history of destructive
psychotic episodes. Under the surface in Tom's network, however, were concerns of
another nature about the disruption of an equilibrium in which the vested interests of
many people were jeopardized. A change in Tom's status threatened less leverage or
control over his autonomous strivings. Delicate work on the boundary was required of
the pharmacotherapist to accommodate the patient's need and the network's invest-
ment in maintaining an equilibrium. Medication often becomes the focal point of this
kind of negotiation process, which is complex and goes far beyondjust a consideration
ofneurochemical process.
Thus, a system's conceptual framework can enable the pharmacotherapist to sort
out and workwith thecomplex intrapsychic, interpersonal, inter-familial, institutional,
and societal forces that are often set in motion by the transactions that surround
prescribing psychoactive medication. These forces can have a profound effect on the
psychosocial therapeutic process. There is no doubt that psychoactive medication can
be a powerful facilitator of therapy, particularly when it is used by the patient as a
resource over which he exerts choice andcontrol, rather than one which he is subjected
to or is forced to comply with. On the other hand, the same medication, even at the
same doses, can be fused with forces within and outside the patient that are aimed at
destroyingexperience andkeeping thepatient locked ih a sickand discredited role. The
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subtle and overt self-serving pressures in the system to view schizophrenia as mainly
disordered chemistry may help to control or abort psychosis, but they can also
insidiously reinforce and perpetuate the schizophrenic problem. It is not just the
medication that needs tobe metabolized by thepatient. Thedynamic forces within the
system must be metabolized by the pharmacotherapist and in a coherent way brought
back into the treatment ifthe patient is to be helped by medication and not harmed.
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